ATAI vs CTAS · rev $4.1M vs P/E 51, rev $11.26B
ATAI Life Sciences BV (ATAI) versus Cintas Corporation (CTAS) — a side-by-side from cached financials, not a winner call.
ATAI Life Sciences BV (ATAI) is a biotechnology company listed on US.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Latest reported ATAI revenue for 2025-12-31 was $4.1M. Net income was -$660.0M. Revenue was up 1227.6% from 2024-12-31 to 2025-12-31. ATAI currently screens at market cap $555.8M.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
ATAI currently screens at market cap $555.8M. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Not investment advice. Open the ATAI and CTAS stock pages for the full models.
Not investment advice.